[Avatrombopag combined with standard immunosuppressive therapy in the treatment of severe aplastic anemia with hepatic impairment in six patients]

Zhonghua Xue Ye Xue Za Zhi. 2022 Nov 14;43(11):952-955. doi: 10.3760/cma.j.issn.0253-2727.2022.11.012.

[Article in Chinese]

Authors

J P Li¹, W R Yang¹, Y Li¹, Y Z Xiong¹, L Ye¹, H H Fan¹, K Zhou¹, Y Yang¹, G X Peng¹, X Zhao¹, L P Jing¹, L Zhang¹, F K Zhang¹

Affiliation

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.

PMID: 36709188
PMCID: PMC9808865
DOI: 10.3760/cma.j.issn.0253-2727.2022.11.012

No abstract available

MeSH terms

Anemia, Aplastic* / complications
Anemia, Aplastic* / therapy
Antilymphocyte Serum
Cyclosporine
Humans
Immunosuppression Therapy
Immunosuppressive Agents / therapeutic use
Thiazoles

Substances

avatrombopag
Immunosuppressive Agents
Thiazoles
Antilymphocyte Serum
Cyclosporine

Grants and funding

基金项目：国家科技重大专项（2017ZX09304024）；中国医学科学院中央级公益性科研院所基本科研业务费项目（2020-RW310-002）